Repligen Corp. 10-Q Summary: Quarter Ended June 30, 2001
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2001, for Repligen Corporation, a biotechnology company developing therapeutic products for pediatric diseases (autism, leukemia, mitochondrial disease) and manufacturing Protein A products for antibody purification. The company operates as a single segment with significant revenue concentration.
Key Financial Metrics
| Metric | Q2 2001 | Q2 2000 |
|---|---|---|
| Total Revenues | $712,536 | $660,794 |
| Net Loss | $(1,343,509) | $(970,943) |
| Loss Per Share (Basic/Diluted) | $(0.05) | $(0.04) |
| Cash and Cash Equivalents | $12,088,869 | $17,208,484 |
| Total Marketable Securities | $16,012,583 | N/A |
| Working Capital | $26,530,000 | N/A |
| Product Gross Margin | 50% | 41% |
Liquidity: Total cash, cash equivalents, and marketable securities totaled approximately $28.1 million at June 30, 2001. The company reported no long-term debt.
Material Changes vs. Prior Period
- Revenue: Increased 8% year-over-year to $713,000, driven by a 28% increase in product revenues ($713,000 vs. $556,000) due to the timing of large-scale Protein A orders. Conversely, R&D and other revenues dropped to zero from $30,000 and $75,000 respectively, as prior year figures included non-recurring licensing and termination fees.
- Expenses: Total costs and expenses rose 12% to $2.4 million. R&D expenses increased 32% to $1.43 million due to higher drug development costs. SG&A expenses decreased 16% to $617,000, primarily due to the absence of non-cash warrant charges recorded in the prior year.
- Cash Flow: Net cash used in operating activities increased to $1.8 million (from $0.6 million), driven by the net loss and increases in inventory and prepaid expenses. Investing activities used $2.3 million primarily for the purchase of marketable securities.
Outlook, Risks, and Contingencies
Management Commentary: Management believes current cash resources are sufficient to fund operations and capital expenditures for the next 24 months. The company is advancing clinical trials for Secretin (autism), CTLA4-Ig (stem cell transplantation), and Uridine (mitochondrial disease).
Legal Proceedings:
- Pro-Neuron Litigation: Pro-Neuron, Inc. sued Repligen and UCSD to void a December 2000 license agreement regarding Uridine. Repligen intends to defend vigorously; a loss could limit commercialization of Uridine.
- BMS Patent Dispute: Repligen and the University of Michigan are litigating against Bristol-Myers Squibb regarding inventorship of patents covering CTLA4. Failure to obtain shared ownership could restrict commercialization of CTLA4-Ig.
Risks: The company faces risks related to FDA approval timelines, clinical trial results, and the ability to secure future financing if needed. Revenue concentration is high, with one customer accounting for approximately 70% of revenues in the quarter.
Investor Verification Checklist
- Verify the status of the Pro-Neuron lawsuit regarding the Uridine license and potential impact on the mitochondrial disease pipeline.
- Confirm the progress of the FDA review for the synthetic porcine secretin product and the likelihood of milestone payments to ChiRhoClin.
- Assess the dependency on the single customer representing 70% of Q2 revenues and the stability of the Protein A supply agreement with Amersham Pharmacia Biotech.
- Review the timeline and budget for the Phase 2 clinical trials of Secretin and CTLA4-Ig to ensure the 24-month liquidity runway remains accurate.